论文部分内容阅读
美国食品与药品监督管理局(FDA)在2014年6月20日批准了新的抗菌药物Sivextro(tedizolid phosphate)的上市申请。Sivextro可用于治疗甲氧西林敏感或耐药的金黄色葡萄球菌、链球菌属、粪肠球菌等病原菌引起的皮肤软组织感染,有静脉和口服两种剂型。Sivextro可用于危及生命的严重感染的治疗。获得旨
The US Food and Drug Administration (FDA) approved the listing of the new antibiotic Sivextro (tedizolid phosphate) on June 20, Sivextro can be used to treat skin and soft tissue infections caused by methicillin-sensitive or resistant Staphylococcus aureus, Streptococcus, Enterococcus faecalis and other pathogens, both intravenous and oral dosage forms. Sivextro can be used for the treatment of serious life-threatening infections. Obtain purpose